Andrea Charles | 11/04/2012
With budget cuts hitting hard in the R&D field, it is imperative to validate the worth of predictive methods internally as they continue to facilitate the reduction in late stage drug attrition. But the challenges remain: how do we cost-effectively develop and implement these in-vitro methods as accurately and as early in the drug discovery process as possible?Jorrit J. Hornberg, PhD Head of Section In Vitro Studies, Exploratory Toxicology at Lundbeck, speaks to Andrea Charles fro...
To continue reading this story Click Here
Upcoming Events
Pharmaceutical Launch Excellence Summit
2 - 3 December, 2025
UK
Register Now |
View Agenda |
Learn More